AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Boosting Immunology Pipeline
ABBV sits 27% above its 52-week low of $181.73.
Summary
AbbVie announced it will acquire Apogee Therapeutics for $10.9 billion in cash, a significant move to build out its next-generation immunology pipeline. This substantial acquisition is a strategic investment in a key therapeutic area, impacting AbbVie's long-term growth prospects. The article also reported CRH's $8.5 billion acquisition of Arcosa, which was previously announced and confirmed earlier today.
At the time of this announcement, ABBV was trading at $231.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $408.7B. The 52-week trading range was $181.73 to $244.81. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.